Panhandle Health brings integrated healthcare to Nebraska

Panhandle Mental Health Center, now known as Panhandle Health Group (PHG), is aiming to expand its care delivery to create a holistic, integrated health-care environment, reports the Star Herald.

“Nationwide, healthcare facilities are turning toward this approach to care,” said Phil Darley, assistant executive director with PHG.

PHG will begin offering basic primary care, walk-in clinic services, DOT physicals, school sports physicals, wellness checks and more.

PHG has also announced that some of its other offices across Nebraska will become virtual clinics, where patients can schedule clinical session and attend those sessions online via the HIPAA-compliant Secure Telehealth system.

“It really opens up an opportunity to help the rural frontier area,” Darley said.

PHG is adding additional labs, exam rooms, office space and medical staff as it continues to expand and offer more healthcare options to the community.

“We are changing the way we do things, the way we think about things, the expectations of the staff and the way we commit to our community,” Darley said. “The whole idea is to have providers working together, and bringing services together, that will allow a person to come into one building and get the care that they need, not only physically but emotionally, mentally and spiritually."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.